Comparative Pharmacology
Head-to-head clinical analysis: PANTOPAQUE versus VASCORAY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PANTOPAQUE versus VASCORAY.
PANTOPAQUE vs VASCORAY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Pantopaque is an iodinated oil-based contrast agent that attenuates X-rays, allowing visualization of the subarachnoid space during myelography. It acts as a positive contrast medium by increasing the absorption of X-rays in the cerebrospinal fluid.
VASCORAY is a fixed combination of iodixanol and calcium sodium edetate. Iodixanol is a nonionic, dimeric, isotonic iodinated contrast medium that increases radiographic contrast by attenuating X-rays. Calcium sodium edetate chelates calcium, potentially reducing contrast-induced nephropathy risk.
Adults: 5-15 mL (6-18 g iophendylate) intrathecally for myelography via lumbar puncture. No repeated dosing.
0.5-1.0 mL/kg intravenously as a single dose, not to exceed 5 mL/kg total.
None Documented
None Documented
Terminal elimination half-life is approximately 6 hours in patients with normal renal function. In renal impairment, half-life is significantly prolonged (up to 24–48 hours in severe impairment), requiring dose adjustment or avoidance.
Terminal elimination half-life of 8-12 hours in patients with normal renal function; prolonged in renal impairment.
Primarily renal (glomerular filtration) with approximately 60-70% of the dose excreted unchanged in urine within 24 hours. Biliary/fecal excretion accounts for less than 5% of the administered dose; minor metabolism occurs, but the majority is eliminated unchanged via kidneys.
Primarily renal (90% unchanged), with 10% biliary/fecal.
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent